← All Soleno Therapeutics INC filings

Soleno Therapeutics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SLNO
Soleno Therapeutics INC
10-K/A: Soleno Therapeutics 10-K/A Filing Summary
Soleno Therapeutics files an amendment to its 2025 Annual Report to include required Part III disclosures regarding corporate governance and executive compensation.
NASDAQ
SLNO
Soleno Therapeutics INC
10-K: Soleno Therapeutics Achieves Profitability Post-VYKAT XR Launch
Soleno Therapeutics, Inc. reported its first profitable year in 2025, driven by $190.4 million in VYKAT XR sales following its FDA approval for Prader-Willi syndrome.
NASDAQ
SLNO
Soleno Therapeutics INC
10-K: Soleno Therapeutics Faces FDA Hurdle for Prader-Willi Syndrome Drug, Eyes March Decision
Soleno Therapeutics awaits a critical FDA decision in March 2025 for its DCCR drug targeting hyperphagia in Prader-Willi syndrome, while navigating financial losses and building its commercial infrastructure.
NASDAQ
SLNO
Soleno Therapeutics INC
10-K: Soleno Therapeutics Submits 10-K Filing, Outlines Path to Potential DCCR Approval
Soleno Therapeutics' 10-K filing details the company's financials, clinical trial progress, and plans for its lead drug candidate, DCCR, targeting Prader-Willi syndrome.